Industry: Biomedical Region: Germany Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A German company, founded in 2016, is a CDMO company that provides end-to-end development, manufacturing services and innovative products for biotechnology and pharmaceuticals. The mission of the enterprise is to bring biotechnology and pharmaceutical products to the market in a fast and effective way, aiming at providing innovative biopharmaceutical solutions. Biotechnology covers all aspects of upstream and downstream production processes, with emphasis on cell destruction using its patented technology. The pharmaceutical sector specializes in the development and technology transfer of nanoparticles and microparticle preparations.
Enterprise technology introduction:
1. Biotechnology production
Enterprises have the fermentation ability of various microorganisms, producing yeast, bacteria and microalgae. The team focused on optimizing the planting process to obtain higher biomass and product yield.
2. Cell fragmentation technology
Using its own method and equipment for cell disruption, this method is continuous, efficient and automatic, and can be easily extended to high throughput and industrial applications. This method is suitable for the decomposition of various biological materials such as microorganisms, mammalian cells and plant leaf extracts.
3. Technology transfer
Through experience to understand the needs of customers, the company has established nano-particles and micro-particle formulations to provide technology transfer services to improve GMP compliance and efficiency. Through the detailed evaluation of product and process parameters, the comparability of products before and after technology transfer is ensured.
Cooperation mode:
Seek partners who need biotechnology and pharmaceutical CDMO services in China.